This study also showed a non-significant 17% reduction in albuminuria.67 The AWARD-7 study analyzed the efficacy of dulaglutide in patients with DM2 and moderate-severe CKD (mean eGFR 38 ml/min/1.73 m2)
In terms of safety, the safety profile of Retatrutide in patients with MASLD is similar to that observed in the broader population with obesity
[2] The safety profile of Orforglipron was consistent with existing GLP-1 therapies, with the most common adverse events being mild to moderate gastrointestinal symptoms such as diarrhea, nausea, dyspepsia, and constipation
Youll have the chance to learn more about Semaglutide injection benefits and discuss how to fit regular treatments into your routine
Vitamin B12 deficiency and use of proton pump inhibitors: a systematic review and meta-analysis
Mundil, D., Cameron-Vendrig, A